HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

In a Q&A posted to FDA’s website, new CFSAN Director Susan Mayne says she’s “trying to learn, as rapidly as I can, everything I can about the safety of foods and cosmetics.” More news in brief.

You may also be interested in...



WEN Attorneys Meet With Top FDA Officials In ‘Continued Cooperation’

CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.

CIR Expert Panel Wants Nano Data For Ingredient Reviews

Are nanoparticle data necessarily relevant to every ingredient assessment undertaken by Cosmetic Ingredient Review’s independent expert panel? Let us be the judge of that, the panel said on 27 September at its 162nd meeting.

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS019754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel